# Orthostatic intolerance in adults with long COVID was not associated with postural orthostatic tachycardia syndrome

3

## Ann Monaghan<sup>1</sup>, Glenn Jennings<sup>1</sup>, Feng Xue<sup>1</sup>, Lisa Byrne<sup>2</sup>, Eoin Duggan<sup>1,2</sup>, Roman Romero Ortuno<sup>1,2</sup>\*

- <sup>6</sup> <sup>1</sup>Discipline of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland
- <sup>7</sup> <sup>2</sup>Falls and Syncope Unit, Mercer's Institute for Successful Ageing, St James's Hospital, Dublin,
- 8 Ireland
- 9 \* Correspondence:
- 10 Prof. Roman Romero-Ortuno, 6th Floor, Mercer's Institute for Successful Ageing (MISA), St
- 11 James's Hospital, Dublin 8, Ireland. Telephone: +353 1 896 3555. Fax: +353 1 896 3407. Email:
- 12 romeroor@tcd.ie

13

## Keywords: Long-COVID; Orthostatic Intolerance; Hemodynamics; Tilt-Table Test; Postural Orthostatic Tachycardia Syndrome.

- 16
- 17 Abstract

18 In this observational cross-sectional study, we investigated predictors of orthostatic intolerance (OI)

- 19 in adults with long COVID. Participants underwent a 3-minute active stand (AS) with Finapres®
- 20 NOVA, followed by a 10-minute unmedicated 70-degree head-up tilt test. 85 participants were
- 21 included (mean age 46 years, range 25-78; 74% women), of which 56 (66%) reported OI during AS
- 22 (OI<sub>AS</sub>). OI<sub>AS</sub> seemed associated with female sex, more fatigue and depressive symptoms, and greater
- 23 inability to perform activities of daily living (ADL), as well as a higher heart rate (HR) at the lowest
- 24 systolic blood pressure (SBP) point before the  $1^{st}$  minute post-stand (mean HR<sub>nadir</sub>: 88 vs 75 bpm,
- P=0.004). In a regression model also including age, sex, fatigue, depression, ADL inability, and peak
   HR after the nadir SBP, HR<sub>nadir</sub> was the only OI<sub>AS</sub> predictor (OR=1.09, 95% CI: 1.01-1.18, P=0.027).
- 27 22 participants had initial (iOH) and 5 classical (cOH) orthostatic hypotension, but neither correlated
- with  $OI_{AS}$ . 71 participants proceeded to tilt, of which 28 had OI during tilt ( $OI_{tilt}$ ). Of the 53 who had
- 29 a 10-minute tilt, 7 (13%) fulfilled hemodynamic postural orthostatic tachycardia syndrome (POTS)
- 30 criteria, but 6 did not report  $OI_{tilt}$ .  $OI_{AS}$  was associated with a higher initial HR on AS, which after 1
- 31 minute equalized with the non- $OI_{AS}$  group. Despite these initial orthostatic HR differences, POTS
- 32 was infrequent and largely asymptomatic. ClinicalTrials.gov Identifier: NCT05027724
- 33 (retrospectively registered on August 30, 2021).
- 34
- 35
- 5.
- 36

It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID

#### 37 1 Introduction

38 Long COVID or post-COVID-19 syndrome first gained recognition among social support groups and 39 later in scientific and medical communities (Yong, 2021). This condition is not well understood as it 40 affects COVID-19 survivors at all ages and levels of disease severity, with or without pre-existing 41 comorbidities, and regardless of hospitalisation status (Vanichkachorn et al., 2021; Yong, 2021). A 42 common symptom is fatigue, with or without organ-specific symptoms (Jennings et al., 2021;Rogers 43 et al., 2021), which may result in negative impacts on resumption of functional and occupational 44 activities (Yan et al., 2021). A systematic review reported that symptoms of mild COVID-19 may 45 persist after 3 weeks in a third of patients (van Kessel et al., 2021). Another study reported that up to one in four patients with mild COVID-19 were still experiencing symptoms after one year (Rank et 46 47 al., 2021); however, data on the exact prevalence and long-term effects of long COVID are still 48 lacking (Zarei et al., 2021), with an urgent need for research in different populations and settings 49 (Michelen et al., 2021). To aid clinicians and researchers, on 6 October 2021 the World Health 50 Organization (WHO) issued a clinical case definition of post COVID-19 condition, obtained by a 51 Delphi consensus (WHO, 2021), as follows: "Post COVID-19 condition occurs in individuals with a 52 history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of 53 COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative 54 diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also 55 others, which generally have an impact on everyday functioning. Symptoms may be new onset,

56 following initial recovery from an acute COVID-19 episode, or persist from the initial illness.

- 57 Symptoms may also fluctuate or relapse over time".
- 58 The neurological and cardiovascular overlap in some long COVID symptoms, and in particular the
- 59 reported occurrence of orthostatic intolerance (OI) (Dani et al., 2021;Paterson et al., 2021;Shah et al.,
- 60 2021), have raised the hypothesis as to whether some long COVID patients could have measurable
- autonomic nervous system impairments (Del Rio et al., 2020;Goldstein, 2020;Keyhanian et al.,
- 62 2020;Barizien et al., 2021;Becker, 2021;Larsen et al., 2021) such as orthostatic hypotension (OH) or
- 63 postural orthostatic tachycardia syndrome (POTS) (Blitshteyn and Whitelaw, 2021;Johansson et al.,
- 64 2021;Raj et al., 2021). In this light, we conducted a cross-sectional observational study on a cohort of
- 65 long COVID participants to fulfil the following objectives: (1) establish the prevalence of OI, both
- 66 during an active stand (AS) test and a tilt test; (2) establish the prevalence of OH and POTS in this
- 67 cohort; and (3) study haemodynamic and non-haemodynamic predictors of OI.

## 68 2 Methods

## 69 2.1 Study and cohort description

- 70 This was a cross-sectional observational study on a participant cohort recruited for the TROPIC
- 71 (Technology assisted solutions for the Recognition of Objective Physiological Indicators of post-
- 72 Coronavirus-19 fatigue) investigation at Trinity College Dublin and St James's Hospital Dublin,
- 73 Ireland. The study received full ethical and regulatory approvals. For the reporting, we followed
- 74 STROBE guidelines (von Elm et al., 2007).
- 75 Participants were eligible for inclusion under all the following criteria: (1) age 18 years or older; (2)
- history of confirmed or suspected SARS-CoV-2 infection; (3) experiencing prolonged symptoms
- such as fatigue; (4) able to mobilise independently (with or without aid); (5) able to transfer
- independently or with minimal assistance of one person from lying to standing; and (6) able to give
- 79 informed consent.

- 80 Participants were recruited from the following sources in our hospital: (1) falls and syncope unit; (2)
- 81 geriatric day hospital; (3) post COVID-19 outpatient clinic; (4) staff who had contracted COVID-19;
- 82 and (5) participants from earlier post-COVID-19 research who had consented to be contacted for
- further studies. In addition, we also considered (6) self-referrals. COVID-19 and non-COVID-19
- 84 exclusion criteria for enrolment are outlined in the Supplementary Information (section 1).
- 85 Prior to enrolment, participants were provided with a Participant Information Leaflet explaining the
- 86 aims and procedures of the study. All participants provided explicit, informed, and voluntary consent
- to partake in the study, were explained the benefits and risks of participating in the research, and had
- 88 the opportunity to discuss the study and ask questions. Participants were given the opportunity to
- 89 withdraw from the study at any point and to forego completing components of the assessment
- 90 protocol as desired.

## 91 2.2 Procedures

- 92 Participants underwent a 3-minute active stand (AS) with Finapres® NOVA, followed by a 10-
- 93 minute unmedicated 70-degree head-up tilt test. During both, participants had frontal lobe
- 94 oxygenation monitoring via PortaLite® near-infrared spectroscopy (NIRS). All testing procedures
- 95 complied with the local hand hygiene, sanitation, personal protective equipment (PPE), and research
- training protocols. We also considered international best practice recommendations for autonomic
- 97 testing during the COVID-19 pandemic (Figueroa et al., 2020;Guaraldi et al., 2020;Sinn et al., 2021).
- 98 For the active stand, participants underwent a lying-to-standing orthostatic test with non-invasive
- beat-to-beat blood pressure monitoring using digital photoplethysmography (Finapres® NOVA,
- 100 Finapres Medical Systems, Amsterdam, The Netherlands). The height correction unit was zeroed and
- 101 implemented as per manufacturer's specifications. A 5-lead continuous electrocardiogram (ECG) was
- 102 acquired throughout the test. During the supine rest period, an oscillometric brachial blood pressure
- 103 measurement was obtained from the non-monitored (right) arm for calibration purposes, once the
- 104 PhysioCal repetition rate was 70 beats or more (Wesseling, 1996). After at least 5 minutes of
- 105 uninterrupted supine rest, a total lying duration of no more than 10 minutes, and a 10-second 106 countdown, participants were asked to stand, unaided, as quick as possible. The PhysioCal was
- 106 countdown, participants were asked to stand, unaided, as quick as possible. The PhysioCal was
   107 turned off just before the stand and switched back on at 1-minute post-stand. After standing, SBP,
- 108 DBP, and HR were monitored for three minutes. Throughout the recording, participants were asked
- 109 to remain motionless and in silence with the monitored arm (left) resting extended by the side, except
- for reporting any symptoms of concern. Immediately after the stand, and at the end of the test,
- participants were asked to report whether they had felt any symptoms of dizziness, light-headedness,
- 112 or any other abnormal symptoms.
- 113 For the tilt procedure, which was medically supervised and started after a brief non-monitored break
- following AS, participants were affixed to an electrically motorized tilt table with footboard support
- and approximately 10 seconds of travel time between  $0^{\circ}$  and  $70^{\circ}$  (Agasan KT-1060/E, AGA
- 116 Sanitätsartikel GmbH, Löhne, Germany). Throughout the tilt, participants underwent Finapres®
- 117 NOVA monitoring (with PhysioCal on and continuous ECG monitoring) during an initial period of
- 118 uninterrupted supine rest of at least 5 minutes (with a total lying duration of no more than 10
- 119 minutes) and a subsequent head-up tilt to  $70^{\circ}$  for 10 minutes or until symptoms developed. An
- 120 oscillometric brachial blood pressure was also obtained during supine rest. During the head-up tilt
- 121 phase, participants were asked to report whether they felt any symptoms of dizziness, light-
- 122 headedness, or any other abnormal symptoms, at which point participants were offered to be tilted

- down. Even without symptoms, if the head-up tilt elicited hypotension (defined as SBP < 90 mmHg),
- 124 the tilt was aborted.
- 125 For the NIRS-based monitoring of regional cerebral oxygenation of the left frontal lobe during both
- 126 AS and tilt, we used an optical sensor (PortaLite®, Artinis Medical Systems B.V., Elst, The
- 127 Netherlands), applied approximately 3 cm to the left of the midline of the forehead and 3.5 cm above
- 128 the bridge of the nose. A close-woven bandage was affixed around the head over the sensor to
- remove ambient lighting and to exert comfortable pressure for effective contact between the probe
- 130 and the skin.

## 131 2.3 Hemodynamic data extraction

- 132 For SBP, DBP and HR, values were noted at the various timepoints of AS and head-up tilt from the
- 133 Finapres® NOVA display screen in accordance with the following standard operating procedure
- 134 (SOP): baseline values were collected at 60 seconds prior to AS or head-up tilt, and subsequently at
- the start of every minute after each procedure. As regards nadir values, for the AS they were noted at
- 136 the lowest point of SBP following completion of standing and prior to the first minute post-stand; in
- 137 the case of the tilt, they were noted at the lowest point of SBP reached between completion of the
- head-up tilt manoeuvre and prior to the first minute post-tilt. For the AS, we also modelled the peak
  HR after the nadir SBP, defined as the maximum of the HR readings obtained at 1, 2 and 3 minutes.
- 140 NIRS values were noted following the same SOP from a laptop display connected to the PortaLite®
- 141 device via OxySoft® software (version 3.2.70), from which we extracted Tissue Saturation Index
- 142 (TSI) values as the percentage ratio of oxygenated haemoglobin concentration to the total
- 143 concentration of haemoglobin (Claffey et al., 2020).

## 144 **2.4 Orthostatic hypotension definitions**

- Initial orthostatic hypotension (iOH) on AS was defined as a difference of >40 mmHg SBP and/or
   >20 mmHg DBP between baseline and nadir values (Freeman et al., 2011).
- 147
- 148 Classical orthostatic hypotension on AS ( $cOH_{AS}$ ) was defined as a difference of  $\geq 20$  mmHg SBP
- 149 and/or  $\geq 10$  DBP between each baseline value and its minimum reading between minutes 1, 2, and 3
- 150 (Freeman et al., 2011). Nadir values were not included in this definition for clear differentiation with
- iOH and to better reflect  $cOH_{AS}$  as normally measured in routine clinical practice with an interval
- measurement device (Breeuwsma et al., 2018).
- 154 Classical orthostatic hypotension on tilt (cOH<sub>tilt</sub>) was defined as a difference of  $\geq$ 20 mmHg SBP
- and/or  $\geq 10$  DBP between each baseline value and its minimum reading between nadir and minutes 1,
- 156 2, and 3. Nadir was included in this case because iOH is only associated with active rising (Wieling
- 157 et al., 2007).

## 158 2.5 POTS hemodynamic definition

- 159 We computed the maximum HR between nadir and minutes 1 to 10 (or the available minutes in case
- 160 of early tilt termination), to which we subtracted baseline HR, and POTS was defined in
- 161 hemodynamic terms as a difference of  $\geq$ 30 bpm in the absence of cOH<sub>tilt</sub> (Freeman et al., 2011).

## 162 **2.6 Other measures**

163 For the characterisation of the cohort, we collected measures including:

- Demographics: age, sex.
- Anthropometrics: body mass index (Kg/m<sup>2</sup>).
- Proportion of third level education (i.e., primary university degree or higher).
- Past medical history including previous or current smoker, hypertension, heart disease (e.g.,
   previous heart attack, angina, congestive heart failure, atrial fibrillation), diabetes mellitus (yes or
   no).
- Current medications including being on an antihypertensive, beta blocker, antidepressant, or
   benzodiazepine (yes or no).
- COVID-19 history: date of COVID-19 diagnosis; hospitalisation status (at least 1 overnight stay: yes or no); current symptomatology (from a structured questionnaire including 41 possible symptoms: yes or no for each), and interference with activities of daily living (ADL) ("In the past month, I have had too little energy to do the things I wanted to do": yes or no).
- The 11-item Chalder Fatigue Scale (CFQ), a self-rating scale developed to measure the severity
   of physical and mental fatigue (Cella and Chalder, 2010). We employed the Likert scoring
   system, with an overall scale range from 0 (minimum) to 33 (maximum fatigue).
- The 20-item Center for Epidemiological Studies Depression (CES-D) scale (Radloff, 1977).
   Scores range from 0 to 60, with higher scores indicating greater depressive symptoms.
- The 22-item Impact of Event Scale Revised (IES-R) (Creamer et al., 2003), which measured post-traumatic stress disorder (PTSD) symptoms in specific relation to participants' COVID-19 illness (minimum: 0; maximum: 88).
- Five chair stands time as a measure of functional lower extremity strength (Munoz-Bermejo et al., 2021): time (in seconds) it took a participant to transfer as quick as possible from a seated to a standing position and back to sitting five times.

#### 187 2.7 Statistical analyses

188 Statistics were computed with IBM® SPSS® Statistics for Windows, Version 26.0, Armonk, NY:

- 189 IBM Corp. Descriptives were given with count and percentage (%), mean with standard deviation
- 190 (SD), median with interquartile range (IQR), and range. We utilised the SPSS Chart Builder to
- 191 visualise hemodynamic differences between subgroups via cluster line chart with representation of
- 192 95% confidence intervals (CI) around means. To compare characteristics between subgroups, we
- 193 utilised the non-parametric 2-sided Mann-Whitney U test for continuous variables, and the Chi-
- square test for dichotomous characteristics. In the latter case, we used the 2-sided Fisher's exact test
- when at least one cell had an expected count of <5. To establish independent predictors of
- dichotomous group membership, we computed logistic regression models, and for each predictor
- extracted the Odds Ratio (OR) and 95% CI for the OR. Multicollinearity checks were conducted.
- 198 Statistical significance was defined as P<0.05.

## 199 **2.8 Ethical approval**

200 This study received full approval by the St James's Hospital/Tallaght University Hospital Joint

201 Research Ethics Committee (Submission Number: 104: TROPIC; Approval Date: 4 May 2021) and

202 the St James's Hospital Research & Innovation Office (Reference: 6566; Approval Date: 14 May

203 2021). The study was performed in accordance with the ethical standards laid down in the 1964

204 Declaration of Helsinki and its later amendments. All participants gave their informed consent prior

to their inclusion in the study. All aspects of the study were executed in compliance with the General

206 Data Protection regulation (GDPR), and Irish regulations including the Health Research Regulations

and the Data Protection Act 2018.

It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID

#### 208 **3 Results**

- 209 Of 92 consecutive participants recruited to the study between May and September 2021, 85 (92.4%)
- had an AS. Mean age was 46.0 years (SD 10.2, range 25-78), and 63 (74.1%) were women. Overall,
- 211 fatigue was a very prevalent long COVID symptom in this cohort (93.5%), with other common
- 212 (>50%) symptoms being shortness of breath (69.6%), sleeping problems (65.2%), ongoing headaches
- 213 (64.1%), dizziness (63.0%), heart palpitations (60.9%), brain fog (59.8%), muscular pain (54.3%),
- and chest tightness (53.3%). Table 1 shows additional descriptives of the 85 participants who had an
- AS. 36.5% had a BMI in the obesity range ( $\geq$ 30 Kg/m<sup>2</sup>), and 1.2% in the underweight range (<18.5
- $Kg/m^2$ ). The majority (62.4%) had third level education and 42.4% were current or former smokers.
- 217 Other than hypertension (17.6%), prevalences of heart disease and diabetes were very low (<5%),
- and there were no instances of Parkinson's disease or other known conditions with risk of autonomic
- 219 impairment. A fifth were on antidepressant medications and less than 20% were on
- antihypertensives, beta blockers or benzodiazepines. In terms of COVID-19 history, all but 2
- 221 participants were at least 3 months from the onset of COVID-19, a quarter had been hospitalised, and
- 81.2% met criteria for WHO clinical case definition of post COVID-19 condition. Median scores for
- 223 CFQ, CES-D and IES-R were 26, 21 and 26, respectively.
- 224

225 During the AS, 56 participants (65.9%) reported OI<sub>AS</sub>. The frequencies of OI<sub>AS</sub> symptoms were as

- 226 follows: "slightly light-headed" (n=31, 55.4%), "light-headed" (n=15, 26.8%), "dizzy" (n=5, 8.9%),
- 227 "slightly dizzy" (n=4, 7.1%), and "very light-headed" (n=1, 1.8%). 2 of the 85 participants had an
- early AS termination due to non-hypotensive/cardiac  $OI_{AS}$  symptoms (n=1 before the 1<sup>st</sup> minute, and
- n=1 before the 3<sup>rd</sup> minute). Table 1 shows the comparison between  $OI_{AS}$  and non- $OI_{AS}$  subgroups. 22
- 230 (25.9%) participants fulfilled criteria for iOH, and 5 (5.9%) for  $cOH_{AS}$ , and neither of the two 231 (P=0.952 an P=0.654, respectively) were significantly associated with  $OI_{AS}$ .  $OI_{AS}$  was more likely in
- women (P=0.019) and was associated with higher CFQ (P=0.042) and CES-D (P=0.021) scores. The
- presence of  $OI_{AS}$  was more likely to be associated with the activities of daily living impairment
- criterion used for our application of the WHO clinical case definition (P=0.011), with virtually all
- participants with  $OI_{AS}$  (96.3%) reporting too little energy to do the things they wanted to do in the
- 236 past month.

**Table 1**. Clinical characteristics of the overall cohort, as well as comparison between OI<sub>AS</sub> and non-OI<sub>AS</sub> subgroups.

260 OI<sub>AS</sub>: orthostatic intolerance during active stand; SD: standard deviation; BMI: body mass index; IQR: interquartile

261 range; CFQ: Chalder Fatigue Scale; CES-D: Center for Epidemiological Studies Depression scale; IES-R: Impact of

262 Event Scale – Revised; iOH: initial orthostatic hypotension; cOH<sub>AS</sub>: classical orthostatic hypotension during active stand.

263

Characteristic	Overall cohort (n=85)	No OI <sub>AS</sub> (n=29)	OI <sub>AS</sub> (n=56)	Р	
Mean age, years (SD)	46.0 (10.2) (range 25-78)	49.1 (11.9)	44.5 (9.0)	0.075 <sup>a</sup>	
Female sex (%)	74.1	58.6	82.1	$0.019^{b^*}$	
Mean BMI, Kg/m <sup>2</sup> (SD)	28.3 (5.1)	27.2 (4.3)	28.9 (5.4)	0.148 <sup>a</sup>	
Mean 5-chair stands time, seconds (SD)	15.0 (10.4)	12.8 (5.1)	16.4 (12.4)	0.409 <sup>a</sup>	
Third level education (%)	62.4	53.8	69.6	0.164 <sup>b</sup>	
Previous or current smoker (%)	42.4	56.0	40.0	0.182 <sup>b</sup>	
History of hypertension (%)	17.6	20.7	16.1	0.596 <sup>b</sup>	
History of heart disease (%)	3.5	6.9	1.8	0.267 <sup>c</sup>	
History of diabetes (%)	3.5	6.9	1.8	0.267 <sup>c</sup>	
On antihypertensive (%)	16.5	24.1	12.5	$0.220^{\circ}$	
On beta blocker (%)	15.3	13.8	16.1	$1.000^{\circ}$	
On antidepressant (%)	20.0	17.2	21.4	0.647 <sup>b</sup>	
On benzodiazepine (%)	3.5	3.4	3.6	1.000 <sup>c</sup>	
Median days post- COVID-19 diagnosis (IQR)	302.0 (333.0) (range 39 – 655)	249.0 (353.5)	317.5 (297.8)	0.628 <sup>a</sup>	
Hospitalised with COVID-19 (%)	25.9	26.9	27.8	0.936 <sup>b</sup>	
At least 3 months (>91 days) from the onset of COVID-19 (%)	97.6	96.0	98.1	0.547°	
Post COVID-19 symptoms for at least 2 months (%)	98.8	100	98.1	1.000 <sup>c</sup>	
In the past month, I have had too little energy to do the things I wanted to do (%)	83.5	76.0	96.3	0.011°	
Median CFQ score (IQR)	26.0 (8.0)	24.0 (10.0)	27.0 (7.8)	$0.042^{a^*}$	
Median CES-D score (IQR)	21.0 (17.0)	16.0 (16.8)	24.0 (16.0)	0.021 <sup>a*</sup>	
Median IES-R score (IQR)	25.5 (28.8)	18.5 (30.3)	31.0 (28.5)	0.106 <sup>a</sup>	
IOH	25.9	33.3	34.1	0.952 <sup>b</sup>	
cOH <sub>AS</sub>	5.9	3.6	7.5	0.654°	

#### 264

265

266 267 <sup>a</sup>2-sided Mann-Whitney U test; <sup>b</sup>Chi-square test; <sup>c</sup>2-sided Fisher's exact test; <sup>\*</sup>statistically significant (P<0.05).

In terms of the haemodynamic comparison between  $OI_{AS}$  and non- $OI_{AS}$  subgroups (Table 2), participants reporting  $OI_{AS}$  had a higher HR at the lowest SBP point before the first minute post-stand

participants reporting  $OI_{AS}$  had a higher HR at the lowest SBP point before the first minute post-stand (mean HR<sub>nadir</sub>: 88 vs 75 bpm, P=0.004). There were no baseline or subsequent HR differences, or any

270 BP or NIRS differences. In the haemodynamic visualisation in Figure 1, participants' finishing BP

levels (at 3 minutes) seemed higher than at baseline, with 95% CIs around means that clearly did not

overlap in the case of DBP (panel b), but without any suggested differences between OI<sub>AS</sub> and non-

OI<sub>AS</sub> subgroups. On closer inspection, for the overall cohort, there was a statistically significant difference between baseline and 3-minute DBP (mean 81.0 vs 93.1 mmHg, paired samples t-test

275 P<0.001).

276

277

It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID

#### 

Table 2. Haemodynamic comparison between OI<sub>AS</sub> and non-OI<sub>AS</sub> subgroups. AS: active stand; OI<sub>AS</sub>: orthostatic
 intolerance during AS; SD: standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart
 ppm: beats per minute; TSI: tissue saturation index.

#### 

	No OI <sub>AS</sub> (initial and final n=29)	OI <sub>AS</sub> (initial n=56) (final n=54)	Р	
Mean oscillometric baseline SBP, mmHg (SD)	131.9 (13.3) (range 103 – 158)	131.2 (15.0) (range 106 – 169)	0.541 <sup>a</sup>	
AS: mean baseline SBP, mmHg (SD)	135.0 (12.8)	131.7 (14.3)	0.216 <sup>a</sup>	
AS: mean nadir SBP, mmHg (SD)	103.1 (18.9)	99.9 (16.6)	0.500 <sup>a</sup>	
AS: mean SBP at 1 minute, mmHg (SD)	139.8 (18.0)	142.6 (15.8)	0.621 <sup>a</sup>	
AS: mean SBP at 2 minutes, mmHg (SD)	141.0 (15.2)	139.9 (16.7)	0.570 <sup>a</sup>	
AS: mean SBP at 3 minutes, mmHg (SD)	142.0 (12.8)	140.6 (17.0)	0.328 <sup>a</sup>	
Mean oscillometric baseline DBP, mmHg (SD)	80.7 (7.9)	80.9 (9.7)	$0.700^{a}$	
Mean oschlonen ic basenne DBF, mining (SD)	(range 63 – 97)	(range 66 – 109)	0.700	
AS: mean baseline DBP, mmHg (SD)	80.7 (7.4)	81.0 (10.1)	0.947 <sup>a</sup>	
AS: mean nadir DBP, mmHg (SD)	75.8 (13.3)	77.8 (20.2)	$0.868^{a}$	
AS: mean DBP at 1 minute, mmHg (SD)	91.0 (10.2)	93.0 (11.1)	0.419 <sup>a</sup>	
AS: mean DBP at 2 minutes, mmHg (SD)	89.8 (9.3)	93.0 (11.7)	0.233 <sup>a</sup>	
AS: mean DBP at 3 minutes, mmHg (SD)	93.4 (9.3)	93.1 (12.6)	$0.680^{a}$	
AS, maan baseling IID, hom (SD)	67.3 (11.0)	71.4 (12.9)	0.210 <sup>a</sup>	
AS: mean baseline HR, bpm (SD)	(range 49 – 94)	(range 50 – 113)	0.210	
AS: mean nadir HR, bpm (SD)	74.6 (12.3)	88.4 (19.6)	$0.004^{a^*}$	
AS: mean HR at 1 minute, bpm (SD)	79.3 (13.5)	80.0 (15.8)	$0.948^{a}$	
AS: mean HR at 2 minutes, bpm (SD)	80.2 (12.5)	83.7 (16.6)	0.451 <sup>a</sup>	
AS: mean HR at 3 minutes, bpm (SD)	81.1 (13.2)	84.5 (15.6)	0.352 <sup>a</sup>	
AS: peak HR after the nadir SBP, bpm (SD)	83.1 (13.7)	86.5 (16.2)	0.434 <sup>a</sup>	
AS: mean baseline TSL % (SD)	68.9 (3.3)	69.1 (7.4)	0.852 <sup>a</sup>	
AS: mean baseline TSI, % (SD)	(range 61 – 78)	(range 32 – 82)	0.852	
AS: mean nadir TSI, % (SD)	68.0 (3.8)	68.3 (8.3)	0.510 <sup>a</sup>	
AS: mean TSI at 1 minute, % (SD)	67.3 (2.8)	67.6 (8.4)	0.384 <sup>a</sup>	
AS: mean TSI at 2 minutes, % (SD)	67.1 (2.8)	67.4 (8.3)	0.490ª	
AS: mean TSI at 3 minutes, % (SD)	67.4 (3.1)	67.8 (6.1)	0.878 <sup>a</sup>	

2 of the 85 participants had an early AS termination (n=1 before the 1<sup>st</sup> minute, n=1 before the 3<sup>rd</sup> minute), both due to non-hypotensive/cardiac OI<sub>AS</sub> symptoms. <sup>a</sup>2-sided Mann-Whitney U test; <sup>b</sup> Chi-square test; <sup>\*</sup> statistically significant (P<0.05).

311 Fig. 1. Haemodynamic visualisation of OI<sub>AS</sub> (n=56) and non-OI<sub>AS</sub> (n=29) groups; a: systolic blood pressure (SBP); b: diastolic blood pressure (DBP); c: heart rate (HR); d: tissue saturation index (TSI); bpm: beats per minute; CI: confidence

312 interval.

- 313
- 314 315

#### a: systolic blood pressure (SBP)



#### 316 317

#### b: diastolic blood pressure (DBP)



It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID



- In the logistic regression model to investigate predictors of  $OI_{AS}$  (Table 3), the only significant
- 332 predictor after controlling for age, sex, fatigue, depression, ADL inability, and peak HR after the
- nadir SBP,  $HR_{nadir}$  was the only  $OI_{AS}$  predictor (OR=1.09, 95% CI: 1.01-1.18, P=0.027).
- 334

Center for Epidemiological Studies Depression scale; HR: heart rate; SBP: systolic blood pressure; OR: odds ratio; CI:
 confidence interval.

338 339

	OR	95% CI for OR		Р
		Lower	Upper	
Age	0.98	0.91	1.05	0.604
Female sex	1.97	0.32	12.06	0.463
CFQ score	0.96	0.80	1.16	0.666
CES-D score	1.07	0.99	1.16	0.080
In the past month, I have had too little energy to do the things I wanted to do	4.48	0.32	62.08	0.263
HR at nadir	1.09	1.01	1.18	0.027
Peak HR after the nadir SBP	0.97	0.89	1.06	0.495

340

341

342 Of the 85 participants who had an AS, 71 (83.5%) had a tilt table test. 14 participants did not have a 343 tilt for reasons including history of recurrent vasovagal syncope (at least two lifetime episodes), a 344 body weight >120 Kg (tilt table safety limit) or not consenting. All tilt participants had had an AS 345 test. Of them, 28 (39.4%) had OI during tilt (OI<sub>tilt</sub>). The frequencies of OI<sub>tilt</sub> symptoms were as follows: "slightly light-headed" (n=10, 35.7%), "light-headed" (n=8, 28.6%), "slightly dizzy" (n=3, 346 10.7%), "dizzy" (n=2, 7.1%), "very light-headed" (n=1, 3.6%), "head spinning" (n=1, 3.6%), 347 348 "drained" (n=1, 3.6%), "weak" 1 (n=1, 3.6%), and "palpitations" (n=1, 3.6%). No instances of 349 arrhythmia or acute myocardial ischemia were detected in the continuous ECG trace. As regards OI agreement between AS and tilt, 78.6% (n=22) of those who had OI<sub>tilt</sub> had previously reported OI<sub>AS</sub> 350 (P=0.020). 18 of the 71 participants had an early tilt termination due to symptoms (n=2 before the  $2^{nd}$ 351 minute, n=3 before the  $3^{rd}$  minute, n=1 before the  $4^{th}$  minute, n=2 before the  $5^{th}$  minute, n=5 before 352 the  $6^{th}$  minute, n=2 before the  $8^{th}$  minute, and n=3 before the  $10^{th}$  minute). Of all the early 353

- terminations, 13 (72.2%) were terminated because of  $OI_{tilt}$  symptoms (P=0.001). The other 5 early tilt terminations were due to the development of "slight shortness of breath" (n=1), "feet pain" (n=1) and
- for reasons not related to development of symptoms (n=3). No pre-syncope or syncope occurred in any of the participants. All OI<sub>tilt</sub> symptoms were reported as transient.
- 358

359 Section 2 in the Supplementary Information shows the comparison between OI<sub>tilt</sub> and non-OI<sub>tilt</sub>

360 subgroups. 22 participants (33.3% among the 66 with a tilt of at least 3 minutes) fulfilled criteria for

361 cOH<sub>tilt</sub>, and 7 (13.2% among the 53 with a full 10-minute tilt) for POTS, and neither of the two

362 (P=0.916 an P=0.233, respectively) were significantly associated with  $OI_{tilt}$ . Among the 7 POTS 363 participants, 2 had a maximum head-up tilt HR of  $\geq$ 120 beats/minute, 6 had no  $OI_{tilt}$ , 4 had reported

 $OI_{AS}$ , 2 were on beta blockers, and 1 on antihypertensives. In the 18 participants whose tilt was

terminated early, none of the available data fulfilled POTS criteria. As shown in the Supplementary

366 Information, there were no statistically significant differences between OI<sub>tilt</sub> subgroups across other

367 clinical (section 2) or haemodynamic characteristics (sections 3 and 4), and no significant predictors

368 of OI<sub>tilt</sub> in the regression model (section 5).

Table 3. Logistic regression model with predictors of OI<sub>AS</sub>. AS: active stand; CFQ: Chalder Fatigue Scale; CES-D:

It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID

#### 369 4 Discussion

In this study, we investigated predictors of orthostatic intolerance (OI) in adults with long COVID. OI during active stand ( $OI_{AS}$ ) was reported by 66% of our sample and seemed associated with female

372 sex, more fatigue and depressive symptoms, and greater inability to perform activities of daily living, 373 as well as a higher heart rate at the lowest systolic blood pressure point before the first minute post-

374 stand (HR<sub>nadir</sub>). In a regression model also including age, sex, fatigue, depression, ADL inability, and

- 375 peak HR after the nadir SBP, HR<sub>nadir</sub> was the only OI<sub>AS</sub> predictor. 26% of participants had initial and
- 376 6% classical orthostatic hypotension, but neither correlated with OI<sub>AS</sub>. Of the participants who had a
- tilt, 39% had OI during tilt; and of the participants who completed a 10-minute tilt, 13% fulfilled
  hemodynamic POTS criteria, but most cases (6 out of 7) were asymptomatic.
- 379

380 The HR at the time of nadir SBP after stand seemed more important than the peak HR after the nadir 381 SBP as a predictor of OI<sub>AS</sub>. In this light, findings might reflect different baroreceptor-related HR 382 responses in participants with OIAS, possibly due to lower efferent vagus nerve activity, and/or higher 383 sympathetic activation. In this regard, it has been described that with incomplete loss of baroreflex 384 afferents, a mild syndrome of orthostatic tachycardia or orthostatic intolerance may appear; in some 385 cases, it may primarily reflect interruption of efferent right vagus nerve activity, leading to a loss of 386 parasympathetic input to the sinus node, with a consequent increase in heart rate; and in other cases, 387 mild sympathetic activation may occur with stress and provoke tachycardia disproportionate to the 388 increase in blood pressure (Ketch et al., 2002). Indeed, other authors have described the possibility of 389 depressed vagal tone (Leitzke et al., 2020) with or without baroreceptor dysfunction that may lead to 390 tachycardia and heightened cardiac contractility, vascular resistance and venous return (Becker,

391 2020).392

393 While SARS CoV 2 might be able to affect neurovascular integrity via direct cytotoxic or indirect 394 pro-inflammatory mechanisms (Khosravani, 2021), our results are in the context of a high burden of 395 psychological symptoms, which is in keeping with other reports (Bucciarelli et al., 2021;Qi et al., 396 2021). Given our recruitment focus, the proportion of fatigue in our cohort was higher than elsewhere 397 (Akbarialiabad et al., 2021;Lopez-Leon et al., 2021;Sanchez-Ramirez et al., 2021;Sandler et al., 398 2021). For contextualization to our cohort, previous research showed that a CFO score of 29 399 discriminated between chronic fatigue sufferers and controls in 96% of cases [36]; CES-D scores of 400 16 or greater can signal risk for clinical depression (Lewinsohn et al., 1997); and an IES-R score of 401 33 and above is suggestive of PTSD (Creamer et al., 2003). Even though in our regression model the 402 HR<sub>nadir</sub> finding seemed to eclipse previously significant univariate associations with depression and 403 fatigue/ADL inability, adverse psychological states may influence the behaviour of the autonomic 404 nervous system (Peckerman et al., 2003; De Vos et al., 2017); furthermore, in susceptible individuals, 405 discrepancies between predicted and experienced interoceptive signals may engender anxiety during 406 an acute physiological arousal (such as an active stand), which may manifest as transient tachycardia 407 (Miglis and Muppidi, 2017; Owens et al., 2018). 408

- 409 In our cohort there seemed to be evidence of diastolic orthostatic *hyper*tension, fulfilling on average
- 410 the criterion of a rise in DBP  $\geq$ 10 mmHg within 3 minutes following AS (Jordan et al., 2020). The
- 411 pathological significance of this finding is not clear and merits further investigation; indeed,
- 412 orthostatic hypertension has been found in healthy subjects but also associated with higher (including
- 413 hypertension) (Jordan et al., 2020) and lower (Wijkman et al., 2016) cardiovascular risks, with more
- 414 research still needed to clarify its mechanisms and impacts (Jordan et al., 2020). Interestingly, even
- 415 though orthostatic hypertension did not seem related to OI in our cohort, it has been described that
- 416 some patients with chronic OI develop symptoms despite a hypertensive response to standing,

417 suggesting that the symptoms of chronic OI may somehow be elicited by central responses to the inappropriate tachycardia, even in the absence of any actual reduction in perfusion pressure 418

- 419
- 420

(Narkiewicz and Somers, 1998).

421 In a previous study where autonomic testing was conducted a median of 119 days following acute 422 COVID-19 infection, 22% of patients fulfilled the criteria for POTS (Shouman et al., 2021), in 423 contrast with 13% in our sample with a median delay to testing of 302 days. As required for the 424 POTS definition [39], 6 of our 7 hemodynamically identified POTS had chronic symptoms of OI lasting at least 6 months; however, in 6 out of 7 cases they did not have OI<sub>tilt</sub> during testing, meaning 425 426 good tolerability to the tilt challenge and potentially a better clinical prognosis. A previous case 427 report showed no improvement in COVID-19-associated POTS symptoms approximately 5.5 months 428 after symptom onset (Miglis et al., 2020); in a case series of 20 patients, it was reported that most 429 (85%) self-reported residual symptoms 6–8 months after COVID-19, although many felt that they had improved (Blitshteyn and Whitelaw, 2021). Three case reports have documented improvement in 430 431 POTS after COVID-19 infection, with or without pharmacological support (Ishibashi et al., 432 2021;O'Sullivan et al., 2021;Ocher et al., 2021). To build on the anecdotal evidence, longitudinal 433 studies are required to assess the evolution of post-COVID POTS in the same cohorts.

434

435 Our study has limitations. Firstly, from a study design perspective, generalisability of the findings

436 cannot be assumed given the non-probabilistic recruitment. The evidence we presented is cross-

437 sectional and observational, hence causation cannot be inferred. In addition, we did not have a 438 sample of controls, which can be beneficial in the study of long COVID (Amin-Chowdhury and 439 Ladhani, 2021). Statistical underpower is likely, given the many instances where the statistic of 440 choice for comparisons was the Fisher's exact test, and a small sample size that precluded inclusion

441 of a greater number of predictors in the regression models.

442

443 Another limitation is that our testing protocol did not include other standardised autonomic tests such 444 as heart rate variability with paced breathing or blood pressure response to Valsalva maneuver. 445 However, in the same clinical environment, Townsend et al. performed those tests on a different long 446 COVID cohort and reported negative findings (Townsend et al., 2021). Our study did not have more 447 detailed measures of baroreflex function, or any imaging or biomarker information (e.g., 448 hematological, biochemical, immunological). For ethical approval reasons, in some cases our

449 research tilts had to be stopped sooner (e.g., with only mild symptoms) than is often the case for tilts

450 used in clinical practice to look for full symptom reproduction. From a haemodynamic data

451 processing point of view, other studies have extracted the raw data from the Finapres® and

452 performed signal averaging prior to analyses, for example in 5-second bins (van der Velde et al.,

453 2007). While *post-hoc* signal averaging can theoretically reduce the risk of spurious observations due

454 to signal artifacts (Finucane et al., 2019), in this study we followed the direct observation method that

455 is routinely utilised in clinical practice for the contemporaneous clinical assessment of patients.

456

457 In conclusion, in our study OIAS was associated with a higher initial HR on AS, which after 1 minute 458 equalized with the non-OI<sub>AS</sub> group, and POTS was infrequent and largely asymptomatic. The burden 459 of psychological symptoms in this cohort was high and findings may be related to interoceptive 460 mechanisms. However, more research is required to understand the mechanisms and long-term

461 prognosis of autonomic function in long COVID, to better delineate therapies and estimate the need

- 462 for services.
- 463
- 464

It is made available under a CC-BY-NC-ND 4.0 Orthostatic intolerance in long COVID

#### 465 **5** Conflict of Interest

466 The authors declare that the research was conducted in the absence of any commercial or financial467 relationships that could be construed as a potential conflict of interest.

#### 468 **6** Author Contributions

469 Conceptualization: Roman Romero-Ortuno, Ann Monaghan; Methodology: Roman Romero-Ortuno,

470 Ann Monaghan, Lisa Byrne; Clinical data collection: Ann Monaghan, Glenn Jennings, Feng Xue,

471 Eoin Duggan, Roman Romero-Ortuno; Formal analysis and investigation: Roman Romero-Ortuno,

472 Ann Monaghan, Glenn Jennings, Eoin Duggan; Writing – original draft preparation: Roman Romero-

473 Ortuno; Writing – review and editing: Ann Monaghan, Glenn Jennings, Feng Xue, Eoin Duggan,

474 Lisa Byrne; Funding acquisition: Roman Romero-Ortuno; Resources: Roman Romero-Ortuno, Lisa

475 Byrne; Supervision: Eoin Duggan, Lisa Byrne, Roman Romero-Ortuno.

#### 476 **7 Funding**

477 This study (Technology Assisted Solutions for the Recognition of Objective Physiological Indicators

478 of Post-Coronavirus-19 Fatigue: TROPIC Study) was funded by a Grant from Science Foundation

479 Ireland (SFI) under Grant number 20/COV/8493 and supported by SFI Grant number 18/FRL/6188.

480 The funder had no role in the conduct of the research and/or preparation of the article; in study

481 design; in the collection, analysis, and interpretation of data; in writing of the report; or in the

482 decision to submit the paper for publication.

## 483 8 Acknowledgments

484 We are very grateful to our participants for their involvement in the study.

## 485 9 References

- Akbarialiabad, H., Taghrir, M.H., Abdollahi, A., Ghahramani, N., Kumar, M., Paydar, S., Razani, B.,
  Mwangi, J., Asadi-Pooya, A.A., Malekmakan, L., and Bastani, B. (2021). Long COVID, a
  comprehensive systematic scoping review. *Infection*.
- Amin-Chowdhury, Z., and Ladhani, S.N. (2021). Causation or confounding: why controls are critical
   for characterizing long COVID. *Nat Med* 27, 1129-1130.
- Barizien, N., Le Guen, M., Russel, S., Touche, P., Huang, F., and Vallee, A. (2021). Clinical
  characterization of dysautonomia in long COVID-19 patients. *Sci Rep* 11, 14042.
- Becker, R.C. (2020). Anticipating the long-term cardiovascular effects of COVID-19. *J Thromb Thrombolysis* 50, 512-524.
- Becker, R.C. (2021). Autonomic dysfunction in SARS-COV-2 infection acute and long-term
   implications COVID-19 editor's page series. *J Thromb Thrombolysis*.
- Blitshteyn, S., and Whitelaw, S. (2021). Postural orthostatic tachycardia syndrome (POTS) and other
  autonomic disorders after COVID-19 infection: a case series of 20 patients. *Immunol Res* 69, 205-211.
- Breeuwsma, A.C., Hartog, L.C., Kamper, A.M., Groenier, K.H., Bilo, H.J.G., Kleefstra, N., and Van
  Hateren, K.J.J. (2018). Diagnosing orthostatic hypotension with continuous and interval
  blood pressure measurement devices. *J Hum Hypertens* 32, 831-837.
- Bucciarelli, V., Nasi, M., Bianco, F., Seferovic, J., Ivkovic, V., Gallina, S., and Mattioli, A.V.
   (2021). Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID
   syndrome: gender makes a difference. *Trends Cardiovasc Med*.

- 506 Cella, M., and Chalder, T. (2010). Measuring fatigue in clinical and community settings. J
   507 Psychosom Res 69, 17-22.
- Claffey, P., Perez-Denia, L., Rivasi, G., Finucane, C., and Kenny, R.A. (2020). Near-infrared
   spectroscopy in evaluating psychogenic pseudosyncope-a novel diagnostic approach. *QJM* 113, 239-244.
- 511 Creamer, M., Bell, R., and Failla, S. (2003). Psychometric properties of the Impact of Event Scale 512 Revised. *Behav Res Ther* 41, 1489-1496.
- 513 Dani, M., Dirksen, A., Taraborrelli, P., Torocastro, M., Panagopoulos, D., Sutton, R., and Lim, P.B.
  514 (2021). Autonomic dysfunction in 'long COVID': rationale, physiology and management
  515 strategies. *Clin Med (Lond)* 21, e63-e67.
- 516 De Vos, A., De Keyser, J., and De Raedt, S. (2017). Role of infarct location and pre-existing
   517 depression on cardiac baroreceptor sensitivity in subacute ischemic stroke. *Acta Neurol Belg* 518 117, 655-659.
- 519 Del Rio, R., Marcus, N.J., and Inestrosa, N.C. (2020). Potential Role of Autonomic Dysfunction in
   520 Covid-19 Morbidity and Mortality. *Front Physiol* 11, 561749.
- Figueroa, J.J., Cheshire, W.P., Claydon, V.E., Norcliffe-Kaufmann, L., Peltier, A., Singer, W.,
   Snapper, H., Vernino, S., Raj, S.R., and American Autonomic, S. (2020). Autonomic function
   testing in the COVID-19 pandemic: an American Autonomic Society position statement. *Clin Auton Res* 30, 295-297.
- Finucane, C., Van Wijnen, V.K., Fan, C.W., Soraghan, C., Byrne, L., Westerhof, B.E., Freeman, R.,
  Fedorowski, A., Harms, M.P.M., Wieling, W., and Kenny, R. (2019). A practical guide to
  active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure
  monitoring. *Clin Auton Res* 29, 427-441.
- Freeman, R., Wieling, W., Axelrod, F.B., Benditt, D.G., Benarroch, E., Biaggioni, I., Cheshire, W.P.,
  Chelimsky, T., Cortelli, P., Gibbons, C.H., Goldstein, D.S., Hainsworth, R., Hilz, M.J., Jacob,
  G., Kaufmann, H., Jordan, J., Lipsitz, L.A., Levine, B.D., Low, P.A., Mathias, C., Raj, S.R.,
  Robertson, D., Sandroni, P., Schatz, I., Schondorff, R., Stewart, J.M., and Van Dijk, J.G.
  (2011). Consensus statement on the definition of orthostatic hypotension, neurally mediated
- 534 syncope and the postural tachycardia syndrome. *Clin Auton Res* 21, 69-72.
- Goldstein, D.S. (2020). The extended autonomic system, dyshomeostasis, and COVID-19. *Clin Auton Res* 30, 299-315.
- Guaraldi, P., Barletta, G., Baschieri, F., Calandra-Buonaura, G., Provini, F., and Cortelli, P. (2020).
   Testing cardiovascular autonomic function in the COVID-19 era: lessons from Bologna's
   Autonomic Unit. *Clin Auton Res* 30, 325-330.
- Ishibashi, Y., Yoneyama, K., Tsuchida, T., and Y, J.A. (2021). Post-COVID-19 Postural Orthostatic
   Tachycardia Syndrome. *Intern Med* 60, 2345.
- Jennings, G., Monaghan, A., Xue, F., Mockler, D., and Romero-Ortuño, R. (2021). A systematic
  review of persistent symptoms and residual abnormal functioning following acute COVID19: Ongoing symptomatic phase vs. post-COVID-19 syndrome. *medRxiv*,
  2021.2006.2025.21259372.
- Johansson, M., Ståhlberg, M., Runold, M., Nygren-Bonnier, M., Nilsson, J., Olshansky, B.,
  Bruchfeld, J., and Fedorowski, A. (2021). Long-Haul Post–COVID-19 Symptoms Presenting
  as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. *JACC: Case Reports* 3, 573-580.
- Jordan, J., Ricci, F., Hoffmann, F., Hamrefors, V., and Fedorowski, A. (2020). Orthostatic
   Hypertension: Critical Appraisal of an Overlooked Condition. *Hypertension* 75, 1151-1158.
- Ketch, T., Biaggioni, I., Robertson, R., and Robertson, D. (2002). Four faces of baroreflex failure:
   hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia.
   *Circulation* 105, 2518-2523.

Keyhanian, K., Umeton, R.P., Mohit, B., Davoudi, V., Hajighasemi, F., and Ghasemi, M. (2020). 555 556 SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. J 557 Neuroimmunol 350, 577436. 558 Khosravani, H. (2021). The Dysfunction is in the Details: Neurovascular Changes in COVID-19. 559 Can J Neurol Sci 48, 1-2. 560 Larsen, N.W., Stiles, L.E., and Miglis, M.G. (2021). Preparing for the long-haul: Autonomic 561 complications of COVID-19. Auton Neurosci 235, 102841. 562 Leitzke, M., Stefanovic, D., Meyer, J.J., Schimpf, S., and Schonknecht, P. (2020). Autonomic 563 balance determines the severity of COVID-19 courses. *Bioelectron Med* 6, 22. 564 Lewinsohn, P.M., Seeley, J.R., Roberts, R.E., and Allen, N.B. (1997). Center for Epidemiologic 565 Studies Depression Scale (CES-D) as a screening instrument for depression among 566 community-residing older adults. *Psychology and Aging* 12, 277–287. 567 Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P.A., Cuapio, A., 568 and Villapol, S. (2021). More than 50 long-term effects of COVID-19: a systematic review 569 and meta-analysis. Scientific reports 11, 16144-16144. 570 Michelen, M., Manoharan, L., Elkheir, N., Cheng, V., Dagens, A., Hastie, C., O'hara, M., Suett, J., 571 Dahmash, D., Bugaeva, P., Rigby, I., Munblit, D., Harriss, E., Burls, A., Foote, C., Scott, J., 572 Carson, G., Olliaro, P., Sigfrid, L., and Stavropoulou, C. (2021). Characterising long COVID: 573 a living systematic review. BMJ Glob Health 6. 574 Miglis, M.G., and Muppidi, S. (2017). Is postural tachycardia syndrome in the head or in the heart? 575 And other updates on recent autonomic research. Clin Auton Res 27, 145-147. 576 Miglis, M.G., Prieto, T., Shaik, R., Muppidi, S., Sinn, D.I., and Jaradeh, S. (2020). A case report of 577 postural tachycardia syndrome after COVID-19. Clin Auton Res 30, 449-451. 578 Munoz-Bermejo, L., Adsuar, J.C., Mendoza-Munoz, M., Barrios-Fernandez, S., Garcia-Gordillo, 579 M.A., Perez-Gomez, J., and Carlos-Vivas, J. (2021). Test-Retest Reliability of Five Times Sit 580 to Stand Test (FTSST) in Adults: A Systematic Review and Meta-Analysis. *Biology (Basel)* 581 10. 582 Narkiewicz, K., and Somers, V.K. (1998). Chronic orthostatic intolerance: part of a spectrum of 583 dysfunction in orthostatic cardiovascular homeostasis? Circulation 98, 2105-2107. 584 O'sullivan, J.S., Lyne, A., and Vaughan, C.J. (2021). COVID-19-induced postural orthostatic 585 tachycardia syndrome treated with ivabradine. BMJ Case Rep 14. 586 Ocher, R.A., Padilla, E., Hsu, J.C., and Taub, P.R. (2021). Clinical and Laboratory Improvement in 587 Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 588 Infection. Case Rep Cardiol 2021, 7809231. 589 Owens, A.P., Low, D.A., Critchley, H.D., and Mathias, C.J. (2018). Emotional orienting during 590 interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological 591 symptomatology in the postural tachycardia syndrome and vasovagal syncope. Auton 592 Neurosci 212, 42-47. 593 Paterson, I., Ramanathan, K., Aurora, R., Bewick, D., Chow, C.M., Clarke, B., Cowan, S., Ducharme, A., Gin, K., Graham, M., Gupta, A., Jassal, D.S., Kazmi, M., Krahn, A., 594 595 Lamarche, Y., Marelli, A., Roifman, I., Ruel, M., Singh, G., Sterns, L., Turgeon, R., Virani, 596 S., Wong, K.K., and Zieroth, S. (2021). Long COVID-19: A Primer for Cardiovascular 597 Health Professionals, on Behalf of the CCS Rapid Response Team. Can J Cardiol 37, 1260-598 1262. 599 Peckerman, A., Lamanca, J.J., Qureishi, B., Dahl, K.A., Golfetti, R., Yamamoto, Y., and Natelson, 600 B.H. (2003). Baroreceptor reflex and integrative stress responses in chronic fatigue syndrome. 601 Psychosom Med 65, 889-895.

- Qi, T., Hu, T., Ge, Q.Q., Zhou, X.N., Li, J.M., Jiang, C.L., and Wang, W. (2021). COVID-19 602 pandemic related long-term chronic stress on the prevalence of depression and anxiety in the 603 604 general population. BMC Psychiatry 21, 380. 605 Radloff, L.S. (1977). The CES-D scale: A self report depression scale for research in the general population. Applied Psychological Measurements 1, 385-401. 606 607 Raj, S.R., Arnold, A.C., Barboi, A., Claydon, V.E., Limberg, J.K., Lucci, V.M., Numan, M., Peltier, 608 A., Snapper, H., Vernino, S., and American Autonomic, S. (2021). Long-COVID postural 609 tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res 31, 365-610 368. 611 Rank, A., Tzortzini, A., Kling, E., Schmid, C., Claus, R., Loll, E., Burger, R., Rommele, C., Dhillon, 612 C., Muller, K., Girl, P., Hoffmann, R., Grutzner, S., and Dennehy, K.M. (2021). One Year 613 after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four 614 Still Suffer from Long-Term Symptoms. J Clin Med 10. Rogers, J.P., Watson, C.J., Badenoch, J., Cross, B., Butler, M., Song, J., Hafeez, D., Morrin, H., 615 616 Rengasamy, E.R., Thomas, L., Ralovska, S., Smakowski, A., Sundaram, R.D., Hunt, C.K., 617 Lim, M.F., Aniwattanapong, D., Singh, V., Hussain, Z., Chakraborty, S., Burchill, E., Jansen, K., Holling, H., Walton, D., Pollak, T.A., Ellul, M., Koychev, I., Solomon, T., Michael, B.D., 618 619 Nicholson, T.R., and Rooney, A.G. (2021). Neurology and neuropsychiatry of COVID-19: a 620 systematic review and meta-analysis of the early literature reveals frequent CNS 621 manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry 92, 932-941. 622 Sanchez-Ramirez, D.C., Normand, K., Zhaoyun, Y., and Torres-Castro, R. (2021). Long-Term 623 Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis. 624 Biomedicines 9. 625 Sandler, C.X., Wyller, V.B.B., Moss-Morris, R., Buchwald, D., Crawley, E., Hautvast, J., Katz, B.Z., Knoop, H., Little, P., Taylor, R., Wensaas, K.A., and Lloyd, A.R. (2021). Long COVID and 626 Post-infective Fatigue Syndrome: A Review. Open Forum Infect Dis 8, ofab440. 627 628 Shah, W., Hillman, T., Playford, E.D., and Hishmeh, L. (2021). Managing the long term effects of 629 covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 372, n136. 630 Shouman, K., Vanichkachorn, G., Cheshire, W.P., Suarez, M.D., Shelly, S., Lamotte, G.J., Sandroni, 631 P., Benarroch, E.E., Berini, S.E., Cutsforth-Gregory, J.K., Coon, E.A., Mauermann, M.L., 632 Low, P.A., and Singer, W. (2021). Autonomic dysfunction following COVID-19 infection: an 633 early experience. Clin Auton Res 31, 385-394. 634 Sinn, D.I., Muppidi, S., Miglis, M.G., and Jaradeh, S. (2021). Autonomic function test during the COVID-19 pandemic: the Stanford experience. *Clin Auton Res* 31, 127-129. 635 636 Townsend, L., Moloney, D., Finucane, C., Mccarthy, K., Bergin, C., Bannan, C., and Kenny, R.A. 637 (2021). Fatigue following COVID-19 infection is not associated with autonomic dysfunction. 638 PLoS One 16, e0247280. 639 Van Der Velde, N., Van Den Meiracker, A.H., Stricker, B.H., and Van Der Cammen, T.J. (2007). 640 Measuring orthostatic hypotension with the Finometer device: is a blood pressure drop of one 641 heartbeat clinically relevant? Blood Press Monit 12, 167-171. 642 Van Kessel, S.a.M., Olde Hartman, T.C., Lucassen, P., and Van Jaarsveld, C.H.M. (2021). Post-acute 643 and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam 644 Pract. 645 Vanichkachorn, G., Newcomb, R., Cowl, C.T., Murad, M.H., Breeher, L., Miller, S., Trenary, M., 646 Neveau, D., and Higgins, S. (2021). Post-COVID-19 Syndrome (Long Haul Syndrome): 647 Description of a Multidisciplinary Clinic at Mayo Clinic and Characteristics of the Initial
- 648 Patient Cohort. *Mayo Clin Proc* 96, 1782-1791.
- Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., and
   Initiative, S. (2007). The Strengthening the Reporting of Observational Studies in

- 651 Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*652 370, 1453-1457.
- Wesseling, K.H. (1996). Finger arterial pressure measurement with Finapres. *Z Kardiol* 85 Suppl 3,
   38-44.
- Who (2021). A clinical case definition of post COVID-19 condition by a Delphi consensus: 6
   October 2021. Available online: <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-</u>
   Post\_COVID-19\_condition-Clinical\_case\_definition-2021.1 (accessed 26 October 2021).
- Wieling, W., Krediet, C.T., Van Dijk, N., Linzer, M., and Tschakovsky, M.E. (2007). Initial
  orthostatic hypotension: review of a forgotten condition. *Clin Sci (Lond)* 112, 157-165.
- Wijkman, M., Lanne, T., Ostgren, C.J., and Nystrom, F.H. (2016). Diastolic orthostatic hypertension
   and cardiovascular prognosis in type 2 diabetes: a prospective cohort study. *Cardiovasc Diabetol* 15, 83.
- Yan, Z., Yang, M., and Lai, C.L. (2021). Long COVID-19 Syndrome: A Comprehensive Review of
   Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans.
   *Biomedicines* 9.
- Yong, S.J. (2021). Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk
   factors, and treatments. *Infect Dis (Lond)* 53, 737-754.
- Zarei, M., Bose, D., Nouri-Vaskeh, M., Tajiknia, V., Zand, R., and Ghasemi, M. (2021). Long-term
   side effects and lingering symptoms post COVID-19 recovery. *Rev Med Virol*, e2289.

## 670 10 Supplementary Material

671 Please see the Supplementary Material section for further information.

## 672 **11 Data Availability Statement**

The datasets generated and analyzed for this study are not publicly available due to ethical approvalreasons.